Gleevec News and Research

RSS
Gleevec is a drug used to treat different types of leukemia and other cancers of the blood, gastrointestinal stromal tumors, skin tumors called dermatofibrosarcoma protuberans, and a rare condition called systemic mastocytosis. It is also being studied in the treatment of other types of cancer. Gleevec blocks the protein made by the bcr/abl oncogene. It is a type of tyrosine kinase inhibitor. Also called imatinib mesylate and STI571.
Set of genes identified in human genome essential for survival, proliferation of human cell lines

Set of genes identified in human genome essential for survival, proliferation of human cell lines

UCLA's Jonsson Comprehensive Cancer Center named among top 10 cancer centers in nation

UCLA's Jonsson Comprehensive Cancer Center named among top 10 cancer centers in nation

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Low doses of imatinib drug can push immune system to combat bacterial infections

Low doses of imatinib drug can push immune system to combat bacterial infections

New study finds increase in use of adjuvant systemic therapy for gastrointestinal stromal tumors

New study finds increase in use of adjuvant systemic therapy for gastrointestinal stromal tumors

Evolution of two protein kinases may hold key to unlocking highly specific cancer drugs

Evolution of two protein kinases may hold key to unlocking highly specific cancer drugs

Franziska Michor named winner of Creative Promise Prize in Biomedical Science

Franziska Michor named winner of Creative Promise Prize in Biomedical Science

Drug similar to Gleevec may help tame some brain cancers

Drug similar to Gleevec may help tame some brain cancers

Yale researcher receives 2015 Frontiers of Knowledge Award in Biomedicine

Yale researcher receives 2015 Frontiers of Knowledge Award in Biomedicine

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Aptose joins Beat AML research collaboration

Aptose joins Beat AML research collaboration

Study reveals how BTK mutation triggers drug resistance in CLL patients

Study reveals how BTK mutation triggers drug resistance in CLL patients

First Edition: May 16, 2014

First Edition: May 16, 2014

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

Biostatistics provides clues to understanding autism: an interview with Dr Knut M. Wittkowski, The Rockefeller University

Biostatistics provides clues to understanding autism: an interview with Dr Knut M. Wittkowski, The Rockefeller University

Old FDA-approved drugs may hold promise for treatment of rare, drug-resistant cancer

Old FDA-approved drugs may hold promise for treatment of rare, drug-resistant cancer

Combination of SYK and FLT3 enzymes promotes progression of acute myelogenous leukemia

Combination of SYK and FLT3 enzymes promotes progression of acute myelogenous leukemia

Study examine effect of high out-of-pocket drug costs for targeted cancer therapies on patients

Study examine effect of high out-of-pocket drug costs for targeted cancer therapies on patients

MIT receives $90M from Ludwig Cancer Research to strengthen interdisciplinary approach to cancer research

MIT receives $90M from Ludwig Cancer Research to strengthen interdisciplinary approach to cancer research

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia